Connor Clark & Lunn Investment Management Ltd. cut its holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 19.6% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 83,673 shares of the company's stock after selling 20,448 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned about 0.17% of Amphastar Pharmaceuticals worth $4,061,000 as of its most recent filing with the SEC.
Other institutional investors have also modified their holdings of the company. Segall Bryant & Hamill LLC acquired a new position in Amphastar Pharmaceuticals in the third quarter valued at approximately $921,000. Quest Partners LLC lifted its holdings in shares of Amphastar Pharmaceuticals by 74.4% in the 3rd quarter. Quest Partners LLC now owns 7,586 shares of the company's stock worth $368,000 after purchasing an additional 3,237 shares during the last quarter. Cornercap Investment Counsel Inc. acquired a new position in Amphastar Pharmaceuticals during the 3rd quarter valued at approximately $263,000. Chase Investment Counsel Corp grew its stake in Amphastar Pharmaceuticals by 45.0% during the 3rd quarter. Chase Investment Counsel Corp now owns 29,000 shares of the company's stock worth $1,407,000 after buying an additional 9,000 shares during the last quarter. Finally, Victory Capital Management Inc. increased its position in Amphastar Pharmaceuticals by 10.9% in the third quarter. Victory Capital Management Inc. now owns 218,531 shares of the company's stock worth $10,605,000 after buying an additional 21,530 shares during the period. Institutional investors own 65.09% of the company's stock.
Several brokerages have recently issued reports on AMPH. StockNews.com downgraded shares of Amphastar Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Friday, November 1st. Needham & Company LLC restated a "hold" rating on shares of Amphastar Pharmaceuticals in a research note on Thursday, August 8th. Wells Fargo & Company began coverage on Amphastar Pharmaceuticals in a report on Friday. They set an "equal weight" rating and a $55.00 price target on the stock. Finally, Piper Sandler decreased their price objective on Amphastar Pharmaceuticals from $71.00 to $66.00 and set an "overweight" rating for the company in a report on Thursday, August 8th. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, Amphastar Pharmaceuticals has a consensus rating of "Hold" and a consensus price target of $60.33.
Read Our Latest Stock Report on AMPH
In other Amphastar Pharmaceuticals news, EVP Rong Zhou sold 4,000 shares of the company's stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $48.35, for a total value of $193,400.00. Following the completion of the sale, the executive vice president now directly owns 118,388 shares of the company's stock, valued at approximately $5,724,059.80. This represents a 3.27 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Richard K. Prins sold 5,000 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $48.80, for a total transaction of $244,000.00. Following the completion of the transaction, the director now directly owns 31,471 shares in the company, valued at $1,535,784.80. This represents a 13.71 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 31,533 shares of company stock worth $1,571,652 over the last ninety days. Company insiders own 27.10% of the company's stock.
Shares of NASDAQ:AMPH opened at $45.46 on Friday. Amphastar Pharmaceuticals, Inc. has a twelve month low of $36.56 and a twelve month high of $65.92. The company has a current ratio of 3.43, a quick ratio of 2.61 and a debt-to-equity ratio of 0.82. The firm has a market cap of $2.19 billion, a P/E ratio of 15.15, a P/E/G ratio of 0.89 and a beta of 0.82. The company has a 50 day moving average of $48.26 and a 200-day moving average of $44.44.
Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Amphastar Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amphastar Pharmaceuticals wasn't on the list.
While Amphastar Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.